Pharmacokinetic modeling frameworks for complex antibody-drug conjugates analytes: clinical pharmacology considerations.
Antibody-drug conjugates (ADCs) present unique pharmacokinetic (PK) challenges due to analyte heterogeneity, dynamic drug-to-antibody ratio (DAR) distributions, target-mediated disposition, and systemic release of cytotoxic payloads. Unlike monoclonal antibodies or small molecules alone, ADCs require integrated modelin...